See more : Humasis Co. Ltd. (205470.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Poolbeg Pharma PLC (POLBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Poolbeg Pharma PLC, a leading company in the Biotechnology industry within the Healthcare sector.
- Gujarat Lease Financing Limited (GLFL.BO) Income Statement Analysis – Financial Results
- F.N.B. Corporation (FNB-PE) Income Statement Analysis – Financial Results
- Consolidated Finvest & Holdings Limited (CONSOFINVT.NS) Income Statement Analysis – Financial Results
- Catalyst Media Group plc (CMX.L) Income Statement Analysis – Financial Results
- Brookfield Asset Management Ltd. (BAM) Income Statement Analysis – Financial Results
Poolbeg Pharma PLC (POLBF)
About Poolbeg Pharma PLC
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 26.00K | 26.00K | 18.00K |
| Gross Profit | -26.00K | -26.00K | -18.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.68M | 2.20M | 414.00K |
| General & Administrative | 3.38M | 3.06M | 2.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 3.38M | 3.06M | 2.03M |
| Other Expenses | -26.00K | 0.00 | 0.00 |
| Operating Expenses | 5.04M | 4.99M | 2.34M |
| Cost & Expenses | 5.04M | 4.99M | 2.34M |
| Interest Income | 0.00 | 209.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 26.00K | 26.00K | 18.00K |
| EBITDA | -4.66M | -4.96M | -3.09M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.69M | -4.99M | -2.34M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 181.00K | 209.00K | 0.00 |
| Income Before Tax | -4.51M | -4.78M | -2.34M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 574.00K | -91.00K | 42.00K |
| Net Income | -3.93M | -4.69M | -2.34M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -9.37 | -0.01 |
| EPS Diluted | -0.01 | -9.37 | -0.01 |
| Weighted Avg Shares Out | 497.59M | 500.00K | 317.23M |
| Weighted Avg Shares Out (Dil) | 500.00M | 500.00K | 317.23M |
Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023
Poolbeg Pharma agrees 12 month option over orphan drug with fast-track potential
Poolbeg Pharma PLC Announces Appointment of Joint Broker
Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate
Poolbeg Pharma PLC Announces TR-1: Notification of Major Holdings
Poolbeg Pharma moves a step closer to locking down IP protection for key asset
Poolbeg Pharma PLC Announces POLB 001 US Patent Update
Poolbeg Pharma PLC Announces Director/PDMR Shareholding
Poolbeg Pharma chairman tops up with share purchase
Source: https://incomestatements.info
Category: Stock Reports